News
Boehringer Ingelheim announced today detailed findings from the Phase III FIBRONEER™-IPF and FIBRONEER™-ILD trials. These studies evaluated nerandomilast, an investigational oral, preferential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback